Thursday , September 20 2018
Home / Resources / Articles / Medical Professionals Speak Up about SGLT2 Inhibitors

Medical Professionals Speak Up about SGLT2 Inhibitors

Jul 23, 2013

Dr. Zachary Bloomgarden, Clinical Professor in the Department of Medicine, Division of Endocrinology at Mount Sinai School of Medicine, New York, New York

“It’s not hype to say that this is a new class of drug that provides patients with a lot of beneficial results.” “The bottom line with this drug is that it controlled blood sugar levels without causing weight gain and caused almost no hypoglycemia. This drug will turn out to be the backbone of new treatments for type 2 diabetes and I use it without hesitation.”

Tim Carlson, MD, Family Practice, St. Petersburg, FL

“I started a couple of patients on Invokana to see the effects. Both of these patients were not at target and I was considering insulin therapy. I was pleased with the results especially in post meal levels. I will continue to start patients on the product as long as there is insurance coverage.”

Karen Brainard, MD Sarasota, FL

“I have not used it yet. I have read some information and concerned about UTI’s. Will look at what others in my area are doing and go from there.”

Samuel Sennicati, Endocrionlogist, Colorado Springs, CO

“We have a couple of employees who have diabetes and I decided to try them on canaglifozin. One of the employees had an almost immediate drop in fasting readings while the other one decided not to take it after reading the package insert. I am going to start on patients after metformin who meet the drug criteria.”

Andrea Sinibaldi ARNP, Little Rock, AR

“I reviewed the information on your website and have decided to wait until there is more patient experience. With all the possible urinary tract problems mentioned in the literature I am going to wait till I feel more comfortable.”

Todd Godwin, MD, Family Medicine Huntington, WV

“I attended a couple of programs in my area and then did some extra research, I think that there is possibly a good future for this medication but I am having getting my patients to use it because of the high copay.”

Copyright © 2013 Diabetes In Control, Inc. 

Pages: 1 2